- Home
- MNSB vs CRDF Comparison
MNSB vs CRDF Comparison
Compare MNSB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | CRDF |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.1M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MNSB | CRDF |
|---|---|---|
| Price | $21.61 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 36.2K | ★ 892.1K |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,367,000.00 | $501,000.00 |
| Revenue This Year | $23.19 | N/A |
| Revenue Next Year | $2.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $15.00 | $1.90 |
| 52 Week High | $22.98 | $5.64 |
Technical Indicators
Market Signals| Indicator | MNSB | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 79.08 | 58.91 |
| Support Level | $19.68 | $2.09 |
| Resistance Level | $21.44 | $2.59 |
| Average True Range (ATR) | 0.51 | 0.14 |
| MACD | 0.23 | 0.04 |
| Stochastic Oscillator | 92.90 | 66.73 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.